Home / Companies / Aclaris Therapeutics, Inc. / 6 Jun 2024
Aclaris Therapeutics, Inc.: meeting of 6 Jun 2024
Votes reported on Form N-PX, item by item
156 Form N-PX filers reported votes at the Aclaris Therapeutics, Inc. meeting of 6 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 66.3% of reported votes for; 40 filers withheld from or voted against at least one nominee.
190 vote records from 62 filers. 4 of the 62 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
212 vote records from 156 filers. 101 of the 148 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
95 vote records from 62 filers. 1 of the 62 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | Split or no vote | Against * | For |
| Fidelity | For | Against * | For |
| Dimensional | No report | Against * | No report |
| State Street and SPDR | Split or no vote | For | For |
| Invesco | Split or no vote | Against * | For |
| Equitable | Abstain or withhold * | Against * | For |
| Charles Schwab | Split or no vote | Against * | For |
| Nuveen and TIAA | Split or no vote | Against * | For |
| ProShares and ProFunds | Split or no vote | Against * | For |
| John Hancock and Manulife | Split or no vote | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | Split or no vote | Against * | For |
| J.P. Morgan | No report | Against * | No report |
| Goldman Sachs | No report | Against * | No report |
| PGIM and Prudential | No report | Against * | No report |
| Jackson National funds | Abstain or withhold * | Against * | For |
| Northern Trust and FlexShares | No report | For | No report |
| SEI | Split or no vote | Against * | For |
| T. Rowe Price | For | Against * | For |
| Lincoln Financial | Split or no vote | For | For |
| Nationwide | Split or no vote | Against * | For |
| Guggenheim and Rydex | Split or no vote | Against * | For |
| BNY Mellon | No report | Against * | No report |
| Principal | Split or no vote | Against * | For |
| Pacific Life funds | For | For | For |
| Global X | Split or no vote | Against * | For |
| Federated Hermes | No report | Against * | No report |
| AllianceBernstein | No report | Against * | No report |
| DWS | Split or no vote | Against * | For |
| Harbor Funds | For | For | For |
| Janus Henderson | No report | Against * | No report |
| Neuberger Berman | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Aclaris Therapeutics, Inc. meeting?
156 Form N-PX filers reported votes at the meeting of 6 Jun 2024. On say-on-pay, 101 of 148 voted against management (68.2%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Aclaris Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Aclaris Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Aclaris Therapeutics, Inc. with a meeting date within three days of 6 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.